---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000131"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:14:57.998560+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential

## Summary
- Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.
- Initial Phase 1 data for IMVT-1402 showed dose-dependent IgG reductions without significant albumin or LDL changes.
- Raised ~$467M net in October 2023 public/private offering; pro forma cash $737M as of Sep 30.
- Expects initial 600mg MAD cohort data for IMVT-1402 in Nov 2023; Phase 2 Graves' data by year-end 2023.
- Phase 3 MG top-line data expected H2 2024; TED data H1 2025; CIDP Phase 2b data H1 2024.

## SEC filing metadata
- accession: 0001764013-23-000131
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/0001764013-23-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/imvt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000131
- JSON: https://secwatch.observer/filing/0001764013-23-000131.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000131.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported financial results for fiscal second quarter and six months ended September 30, 2023.
  - Period: fiscal second quarter and six months ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/0001764013-23-000131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.